CD8A and neoplasm: On day 60 after the adoptive transfer, tumor rejection was observed in 40% of recipient mice with CD8+ T cells from MBTA-treated mice (2 from 6 mice), 100% of recipient mice with CD4+ T cells from MBTA-treated mice, and in 20% of both control groups with CD4+ or CD8+ T cells (Figure 5C).